Biomimetic Nanoparticles Enhance Recovery of Movement Disorders in Parkinson’s Disease by Improving Microglial Mitochondrial Homeostasis and Suppressing Neuroinflammation DOI
Liang Li,

Chunbin Sun,

Shanglin Cai

et al.

ACS Applied Materials & Interfaces, Journal Year: 2025, Volume and Issue: unknown

Published: April 9, 2025

Neuroinflammation is a key risk factor for cognitive impairment, and microglia are the main drivers. Metformin has been shown to suppress inflammation reduce microglial activation, protecting neurons from damage. However, its clinical efficacy limited by low bioavailability metabolic challenges, especially in terms of precise delivery specific targets. To overcome this problem, we developed biomimetic nanoparticles (MePN@BM) enhance targeted metformin. Through homologous targeting, efficiency drugs inflammatory site Parkinson's disease was enhanced improve therapeutic effect. The results showed that MePN@BM effectively delivers metformin brain, promotes autophagy, restores mitochondrial membrane potential, reduces oxidative stress. In (PD) mouse model, improved motor function, repaired dopaminergic neurons, cleared α-synuclein aggregates. Notably, transcriptome analysis revealed enriched inflammation-related pathways, immunofluorescence PD mice treated with had higher levels anti-inflammatory factors lower pro-inflammatory factors. Therefore, it provides promising strategy treatment inflammation-mediated dysfunction.

Language: Английский

New Trends in Brain Shuttle Peptides DOI
Roger Prades, Meritxell Teixidò, Benjamí Oller‐Salvia

et al.

Molecular Pharmaceutics, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 3, 2025

The pharmacological treatment of central nervous system diseases faces significant challenges due to the presence blood–brain barrier (BBB). This naturally protects brain and prevents therapeutics from reaching their targets efficiently. However, BBB allows passage nutrients other molecules that guarantee homeostasis through selective transport mechanisms present at BBB. These provide an opportunity for delivering therapeutic agents into using shuttles. Here we review progress shuttle peptide development 2015 until 2025. We highlight most utilized peptides describe trends in strategies develop new shuttles enhance efficiency. Additionally, compared them with types emphasize toward clinical translation.

Language: Английский

Citations

1
A review on brain-targeting nano-based drug delivery DOI
Peiying Li, Yaoxing Chen, Xiaoling Gao

et al.

Chinese Science Bulletin (Chinese Version), Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 1, 2025

Language: Английский

Citations

0
Biomimetic Nanoparticles Enhance Recovery of Movement Disorders in Parkinson’s Disease by Improving Microglial Mitochondrial Homeostasis and Suppressing Neuroinflammation DOI
Liang Li,

Chunbin Sun,

Shanglin Cai

et al.

ACS Applied Materials & Interfaces, Journal Year: 2025, Volume and Issue: unknown

Published: April 9, 2025

Neuroinflammation is a key risk factor for cognitive impairment, and microglia are the main drivers. Metformin has been shown to suppress inflammation reduce microglial activation, protecting neurons from damage. However, its clinical efficacy limited by low bioavailability metabolic challenges, especially in terms of precise delivery specific targets. To overcome this problem, we developed biomimetic nanoparticles (MePN@BM) enhance targeted metformin. Through homologous targeting, efficiency drugs inflammatory site Parkinson's disease was enhanced improve therapeutic effect. The results showed that MePN@BM effectively delivers metformin brain, promotes autophagy, restores mitochondrial membrane potential, reduces oxidative stress. In (PD) mouse model, improved motor function, repaired dopaminergic neurons, cleared α-synuclein aggregates. Notably, transcriptome analysis revealed enriched inflammation-related pathways, immunofluorescence PD mice treated with had higher levels anti-inflammatory factors lower pro-inflammatory factors. Therefore, it provides promising strategy treatment inflammation-mediated dysfunction.

Language: Английский

Citations

0